Why comparative effectiveness won’t matter to Avastin and Lucentis

July 31st, 2010 | Author: Idhay

by Merrill Goozner

The Center for Medicare and Medicaid Services could save a half billion dollars a year by switching its beneficiaries with macular degeneration to Genetench’s Avastin instead of Genentech’s Lucentis, the Wall Street Journal reported recently. The two drugs are variations of the same molecule.

(…)
Read the rest of Why comparative effectiveness won’t matter to Avastin and Lucentis

2 comments | Tags: Drugs, Health reform | Category: Drugs and pharma